Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now!


View All

Novartis Cosentyx: First Biologic Hidradenitis Suppurativa Treatment After Almost Ten Years

While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB’s bimekizumab, recently approved as Bi...

Find More

Pharma News for AbbVie, Novartis, Avenge Bio, Eli Lilly
AbbVie Presents Phase III CANOVA Study Results; Novartis’ Iptacopan Shows Promise in Phase III Study; Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer; FDA Issues Complete Response Letter for Lebrikizumab; Nedosiran Approveed for Primary Hyperoxaluria Type 1; Orphan Drug Designation to BDC-1001 for Gastric Cancers

AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...

Find More

Pharma News for AbbVie, BioArctic, Coherus
LEQEMBI Intravenous Infusion Approval; Novartis’ Presented Updates on Lutathera; FDA Accepts Submission to Add PH-ILD to YUTREPIA Label; FDA Issues CRL to BLA for Pegfilgrastim-cbqv; FDA Fast Track Designation to Therpay, MWTX-003; EC Approves TEPKINLY (epcoritamab) for R/R DLBCL

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of patients with Polycyt...

Find More

Watershed Moment for Cell Therapies and Complicated Journey of Gene Therapies in Japan

In recent years, the development of cell and gene therapies has provided a new avenue for the treatment of rare disorders. This article will discuss the current and future scenarios of cell and gene therapies in rare disorders with cancer indications as an exception, in Japan. Cell therapy is a treatment in which l...

Find More

Pharma News and Updates for Novartis, Pharming, Cyclerion, Iovance, BPGbio
Novartis Announces the Positive Results of Phase III NATALEE Trial Evaluating Kisqali; FDA Approves Pharming’s Joenja for APDS; FDA Orphan Drug Designation to Cyclerion’s Zagociguat; Iovance Completes BLA Submission for Lifileucel in Advanced Melanoma; BPGbio Announces Partnership with debra of America

Novartis Announces the Positive Results of Phase III NATALEE trial Evaluating Kisqali Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/hu...

Find More

Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval

FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...

Find More

Top 7 Pharma Industry Leaders in 2020 By the Numbers

Pharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, ...

Find More

Diabetic Macular Edema Market | Diabetic Macular Edema Drug Portfolio
Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future

Diabetes is a condition in which the blood glucose (blood sugar) level is abnormally high. Glucose, which is obtained from the food consumed, is the primary source of energy in the body. However, the excess glucose level in the blood can cause health issues over time and can lead to vision disorders like Diabetic R...

Find More

Presbyopia Treatment Market | Novartis | Visus | AbbVie
How will Pharmacotherapies help the growing number of Presbyopes?

Presbyopia is the gradual loss of near-focusing ability that occurs with age—a condition that occurs when people get older and prevails as a quite common one in many individuals. The reasons for this lack of accommodation power are undetermined. It is commonly assumed that this is due to the lens being less elastic...

Find More

Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M

Artios Pharma announces collaboration with Novartis to tap next-generation DDR cancer therapies Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploiting synthetic lethality to create a broad pipeline of precision medicines for cancer treatment, announced a global research collaboration with ...

Find More